Hemoglobin cycling in hemodialysis patients treated with recombinant human
erythropoietin. Background Treatment with recombinant human erythropoietin (rHuEPO) has …

Treatment with erythropoietic-stimulating agents (ESA) has been a major advance for
improving the lives of patients with chronic kidney disease (CKD). Treatment, however …

Hemoglobin variability in epoetin-treated hemodialysis patients. Background Understanding
the clinical variability of hemoglobin measurements in epoetin-treated hemodialysis patients …

Background. Darbepoetin alfa is a unique molecule that stimulates erythropoiesis by the
same mechanism as endogenous erythropoietin. Due to its∼ 3-fold longer half-life and …

Aim: To determine whether extended epoetin alfa dosing schedules of up to once every four
weeks are as effective as weekly dosing in maintaining hemoglobin (Hb) levels in patients …

Background and objectives: Among hemodialysis patients, achieved hemoglobin is
associated with Epoetin alfa dose and erythropoietin responsiveness. A prospective …

Background. Darbepoetin alfa is an erythropoietic agent with a 3‐fold longer elimination half‐
life than recombinant human erythropoietin (rHuEpo), which allows less frequent dosing …

BACKGROUND:: Most patients with end-stage renal disease have chronic anemia caused
by inadequate erythropoietin (EPO) synthesis and require therapy with exogenous EPO to …

Background. Darbepoetin alfa, a glycoprotein that stimulates erythropoiesis by the same
mechanism as endogenous erythropoietin, has a 3-fold longer terminal half-life than …

BACKGROUND: CERA (methoxy polyethylene glycol-epoetin beta), a continuous
erythropoietin receptor activator, was developed to provide stable control of hemoglobin …